Xiaomei Xu

Title: The Innovations of Xiaomei Xu

Introduction

Xiaomei Xu is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of biopharmaceuticals, particularly through his work on semaphorin K1 polypeptides. With a total of 2 patents, his innovations have the potential to impact cellular guidance and physiology.

Latest Patents

Xiaomei Xu's latest patents focus on semaphorin K1. The invention provides methods and compositions relating to semaphorin K1 (sema K1) polypeptides, which regulate cellular guidance and physiology, along with related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells using the disclosed sema K1 encoding nucleic acids or purified from human cells. Additionally, the invention includes isolated sema K1 hybridization probes and primers capable of specifically hybridizing with the disclosed sema K1 genes. It also features sema K1-specific binding agents, such as specific antibodies, and methods of making and using these compositions in diagnosis, therapy, and the biopharmaceutical industry.

Career Highlights

Throughout his career, Xiaomei Xu has worked with notable companies, including Exelixis Pharmaceuticals, Inc. and Exelixis, Inc. His experience in these organizations has contributed to his expertise in the field of biopharmaceuticals.

Collaborations

Xiaomei Xu has collaborated with various professionals, including Yuling Luo, who has been a significant coworker in his endeavors.

Conclusion

Xiaomei Xu's contributions to the field of biopharmaceuticals through his patents on semaphorin K1 highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic approaches.